Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
(NasdaqGM:FULC), CAMBRIDGE, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (R) (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the pricing of its previously announced underwritten public offering of 11,851,853 shares of its common stock at […]